First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 692 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type MOST POPULAR FDA Grants Accelerated Approval to Repotrectinib for Adult and Paediatric Patients... July 8, 2024 Whole-Genome Sequencing Provides Rapid and Accurate Genomic Profiling in Patients with... March 11, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Odronextamab July 22, 2024 Aggressive Prostate Cancer Subtype More Common Than Expected July 31, 2018 Load more HOT NEWS New Low-Powered Implantable Device Monitors Soft Tissue for Signs of Breast... Five Questions with…Jennifer. Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera Investing in volunteers since 2002: The tale of time
